JP Morgan Chase
ABVX

JP Morgan Chase’s Abivax ABVX Stock Holding History

JP Morgan Chase’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600
Closed -$80.9K – 7489
2025
Q4 		$80.9K Buy
+600
New +$65.5K ﹤0.01% 5998

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's ABVX Position: Q2 2026 in Review

JP Morgan Chase reduced its Abivax (ABVX) stake by 99% in Q2 2026, selling an estimated $71.2M and leaving 5,717 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #5028.

JP Morgan Chase first reported a position in ABVX in Q4 2024 and has held it in 5 quarters since. The position peaked at $64.5M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • JP Morgan Chase held 5,717 shares of Abivax worth $550K as of Q2 2026.
  • JP Morgan Chase sold 629,349 Abivax shares in Q2 2026, an estimated $71.2M.
  • Abivax made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5028 holding.
  • JP Morgan Chase first reported a position in Abivax in Q4 2024 and has held it in 5 quarters since.
  • JP Morgan Chase's Abivax position peaked at $64.5M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.